Incidence of Posttransplant Lymphoproliferative Disorder with Belatacept Therapy versus Calcineurin Inhibitor Therapy Alone: Data from One Academic Medical Center
1Division of Renal and Pancreatic Transplant Services, Albany Medical Center, Albany, NY, 2George Mason University, Fairfax, VA, 3UMC Las Vegas, Las Vegas, NV
Meeting: 2022 American Transplant Congress
Abstract number: 1016
Keywords: Kidney transplantation, Post-transplant lymphoproliferative disorder (PTLD)
Topic: Clinical Science » Infection Disease » 28 - PTLD: All Topics
Session Information
Session Time: 7:00pm-8:00pm
Presentation Time: 7:00pm-8:00pm
Location: Hynes Halls C & D
*Purpose: To compare rates of post-transplant lymphoproliferative disorder (PTLD) in patients treated with Belatacept and low-dose calcineurin inhibitors (CNIs) versus patients only treated with standard-dose CNIs.
*Methods: The records of 365 individuals who underwent kidney transplantation from January 2015 through September 2021 at one academic medical center were included in this analysis. Two cohorts of patients were evaluated: Cohort 1 was treated with monthly administration of 5.0mg/kg Belatacept alongside low-dose CNI therapy of mycophenolate and tacrolimus (n=119) and Cohort 2 received standard-dose CNI therapy of mycophenolate, rapamune, and tacrolimus (n=246). Relevant donor and recipient information was analyzed, and endpoints of post-transplant lymphoproliferative disorder were assessed.
*Results: Of the 365 patients enrolled in this study, only four individuals developed PTLD. Cohort 1 had 0% rate of PTLD in patients treated with Belatacept alongside low-dose CNI therapy. Cohort 2 experienced 4 cases of PTLD (1.6%) among individuals treated with standard-dose CNI therapy alone. Two females and two males were affected. Three of these cases were monomorphic PTLD and one case was polymorphic PTLD. The monomorphic PTLD cases developed 615, 905, and 1723 days after transplantation while the polymorphic PTLD occurred 80 days after transplantation. All were EBV seropositive and had no prior history of malignancy.
*Conclusions: Based on this analysis, Belatacept does not appear to pose any increased risk of PTLD in appropriately selected patients. Both cohorts will be monitored many years after transplantation as PTLD can manifest as a long-term complication.
To cite this abstract in AMA style:
Addonizio K, Petrossian G, Hsiao A, Teixeira L, Koizumi N, James R, Patel S, Plews R, Conti D, Ortiz J. Incidence of Posttransplant Lymphoproliferative Disorder with Belatacept Therapy versus Calcineurin Inhibitor Therapy Alone: Data from One Academic Medical Center [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/incidence-of-posttransplant-lymphoproliferative-disorder-with-belatacept-therapy-versus-calcineurin-inhibitor-therapy-alone-data-from-one-academic-medical-center/. Accessed May 11, 2025.« Back to 2022 American Transplant Congress